|  | 
	
	| Sibofimloc |  | Escherichia | Adherence | Phase II trial | Chevalier G, et al. 2021. Microbiome; Reinisch W, et al. 2022. J Gastroenterol Hepatol | 
	|  | 
	
	| Fluorothiazinon | Depiction based on curated SMILES
OH
O
S
F
F
H
3
C
NH
O
N
N
O | Acinetobacter Chlamydia
 Klebsiella
 Pseudomonas
 Salmonella
 | Biofilm TTSS (Type III secretion system)
 Biofilm
 TTSS (Type III secretion system)
 TTSS (SPI-1 encode); TTSS (SPI-2 encode)
 | Preclinical (in vivo) Preclinical (in vivo)
 Preclinical (in vitro)
 Preclinical (in vivo)
 Phase II trial
 | Bondareva NE, et al. 2022. J Antibiot (Tokyo) Zigangirova NA, et al. 2012. Acta Naturae; Koroleva EA, et al. 2015. Biomed Res Int; Zigangirova NA, et al. 2016. J Med Microbiol
 Tsarenko SV, et al. 2023. J Antibiot (Tokyo)
 Sheremet AB, et al. 2018. Biomed Res Int
 Nesterenko LN, et al. 2016. J Antibiot (Tokyo); Zigangirova NA, et al. 2021. J Antibiot (Tokyo)
 | 
	|  | 
	
	| Zosurabalpin | Depiction based on curated SMILES
NH
2
NH
2
N
O
OH
N
H
N
O
N
H
S
CH
3
N
H
O
N
H
O | Acinetobacter | LPS | Phase I trial | Zampaloni C, et al. 2024. Nature; Pahil KS, et al. 2024. Nature; Que W, et al. 2024. Trends Mol Med | 
	|  | 
	
	| N-(2-{(2Z)-2-[1-(1,3-benzodioxol-5-ylmethyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]hydrazinyl}-2-oxoethyl)pyridine-3-carboxamide | Depiction based on curated SMILES
O
N
O
N
H
O
O
N
N
H
N
O | Acinetobacter | Regulation | Preclinical (in vivo) | Trebosc V, et al. 2022. Virulence | 
	|  | 
	
	| Auranofin | Depiction based on curated SMILES
+
Au
H
3
C
O
O
H
3
C
O
O
CH
3
O
O
_
S
O
CH
3
O
O
H
3
C
H
3
C
H
3
C
P | Clostridium | CDT (Clostridium difficile toxin) | Preclinical (in vivo) | AbdelKhalek A, et al. 2019. Int J Antimicrob Agents; Hutton ML, et al. 2020. J Antimicrob Chemother; Abutaleb NS, et al. 2020. Sci Rep | 
	|  | 
	
	| 3-Methylthio-1,4-diphenyl-1H-1,3,4-triazolium | Depiction based on curated SMILES
N
H
3
C
+
N
N
S | Escherichia | Heat-labile toxin (LT) | Preclinical (in vivo) | Hovey BT, et al. 1999. J Mol Biol | 
	|  | 
	
	| 7-[3-methyl-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-2H-isoquinolin-1-one | Depiction based on curated SMILES
N
H
OH
OH
OH
OH
O
O
O
CH
3 | Escherichia | Type 1 fimbriae | Preclinical (in vivo) | Jarvis C, et al. 2016. ChemMedChem | 
	|  | 
	
	| (3R)-5-Oxo-6-(morpholinomethyl)-7-(1-naphthylmethyl)-8-phenyl-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3beta-carboxylic acid lithium salt | Depiction based on curated SMILES
O
_
O
O
N
+
Li
N
O
H
S | Escherichia | Type 1 fimbriae; P fimbriae | Preclinical (in vivo) | Pinkner JS, et al. 2006. Proc Natl Acad Sci U S A | 
	|  | 
	
	| (3R)-5-Oxo-6-(dimethylaminomethyl)-7-(1-naphthylmethyl)-8-phenyl-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3beta-carboxylic acid lithium salt | Depiction based on curated SMILES
_
O
N
H
3
C
N
CH
3
+
Li
O
H
S
O | Escherichia | Type 1 fimbriae; P fimbriae | Preclinical (in vivo) | Pinkner JS, et al. 2006. Proc Natl Acad Sci U S A | 
	|  | 
	
	| (3R)-5-Oxo-6-(dimethylaminomethyl)-7-methyl-8-phenyl-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3beta-carboxylic acid lithium salt | Depiction based on curated SMILES
CH
3
H
3
C
N
_
O
O
+
Li
S
H
N
O
CH
3 | Escherichia | Type 1 fimbriae; P fimbriae | Preclinical (in vivo) | Pinkner JS, et al. 2006. Proc Natl Acad Sci U S A | 
|  | 
	|  |  |  |